- Home
- CVAC vs ORIC Comparison
CVAC vs ORIC Comparison
Compare CVAC & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVAC
- ORIC
- Stock Information
- Founded
- CVAC 2000
- ORIC 2014
- Country
- CVAC Germany
- ORIC United States
- Employees
- CVAC N/A
- ORIC N/A
- Industry
- CVAC Biotechnology: Pharmaceutical Preparations
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- CVAC Health Care
- ORIC Health Care
- Exchange
- CVAC Nasdaq
- ORIC Nasdaq
- Market Cap
- CVAC 637.1M
- ORIC 750.6M
- IPO Year
- CVAC 2020
- ORIC 2020
- Fundamental
- Price
- CVAC $2.54
- ORIC $8.50
- Analyst Decision
- CVAC Hold
- ORIC Strong Buy
- Analyst Count
- CVAC 3
- ORIC 9
- Target Price
- CVAC $10.00
- ORIC $18.75
- AVG Volume (30 Days)
- CVAC 540.3K
- ORIC 499.8K
- Earning Date
- CVAC 11-12-2024
- ORIC 11-12-2024
- Dividend Yield
- CVAC N/A
- ORIC N/A
- EPS Growth
- CVAC N/A
- ORIC N/A
- EPS
- CVAC N/A
- ORIC N/A
- Revenue
- CVAC $70,565,734.00
- ORIC N/A
- Revenue This Year
- CVAC $123.97
- ORIC N/A
- Revenue Next Year
- CVAC N/A
- ORIC N/A
- P/E Ratio
- CVAC N/A
- ORIC N/A
- Revenue Growth
- CVAC 75.11
- ORIC N/A
- 52 Week Low
- CVAC $2.22
- ORIC $6.33
- 52 Week High
- CVAC $6.30
- ORIC $16.65
- Technical
- Relative Strength Index (RSI)
- CVAC 34.97
- ORIC 37.50
- Support Level
- CVAC $2.73
- ORIC $10.06
- Resistance Level
- CVAC $2.97
- ORIC $11.11
- Average True Range (ATR)
- CVAC 0.18
- ORIC 0.81
- MACD
- CVAC -0.01
- ORIC -0.05
- Stochastic Oscillator
- CVAC 7.55
- ORIC 13.00
About CVAC CureVac N.V.
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533.